Creative Biolabs’ expanded primary neuron portfolio includes cortical, hippocampal, dopaminergic, and sensory neurons isolated and characterized under stringent quality control (QC) standards and ...

Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA ® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant ...

A stem cell transplant usually requires you to stay in the hospital for weeks and get frequent checkups for months after you go home. Close monitoring lets your health care team support your recovery ...

Omeros has won U.S. Food and Drug Administration approval of its Yartemlea treatment for an often-fatal complication of stem-cell transplants. Omeros on Wednesday said the approval covers Yartemlea ...

(RTTNews) - Omeros Corp. (OMER), a clinical-stage biopharmaceutical company focused on complement-mediated diseases, oncology, and addictive disorders, today announced its financial results for the ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Kawasaki Disease (KD) is an acute febrile systemic vasculitis of unknown etiology and the leading cause of acquired heart disease among children. The complement system is a major component of innate ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...